9 results match your criteria: "National Institute of Diabetes and Digestive and Kidney Disease (NIDDK).[Affiliation]"
Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.
Dig Dis Sci
December 2023
Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), National Institutes of Health (NIH), Bethesda, USA.
Aims: Evaluate patient-reported liver symptoms during treatment for chronic hepatitis B viral (HBV) infection and associations between changes in symptoms and levels of alanine aminotransferase (ALT) and viral markers.
Methods: Data from 200 participants in the Hepatitis B Research Network Immune Active Trial who completed symptom assessments were analyzed. Patients were treated with tenofovir, with or without peginterferon (TDF + PegIFN vs.
A novel ARPKD mouse model with near-complete deletion of the Polycystic Kidney and Hepatic Disease 1 (Pkhd1) genomic locus presents with multiple phenotypes but not renal cysts.
Kidney Int
September 2023
Polycystic Kidney Disease Section, Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA. Electronic address:
Comparison of CD34 cells isolated from frozen cord blood and fresh adult peripheral blood of sickle cell disease patients in gene correction of the sickle mutation at late-stage erythroid differentiation.
Br J Haematol
September 2021
Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), National Institutes of Health, Bethesda (NIH), Bethesda, MD, USA.
The looming storm: Blood and cytokines in COVID-19.
Blood Rev
March 2021
Department of Hematology and Oncology, St. Joseph University Medical Center, 703 Main Street, Paterson, NJ 07503, USA. Electronic address:
A novel coronavirus termed as COVID-19 by WHO has been the causative agent of an unprecedented pandemic in the history of humanity. The global burden of mortality and morbidity associated with this pandemic continues to increase with each passing day as it is progressively leading to multiorgan dysfunction. In most cases, the cause of death has been attributed to respiratory failure, sepsis, cardiac failure, kidney injury, or coagulopathy.
View Article and Find Full Text PDF18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma.
Endocrinol Diabetes Metab Case Rep
March 2020
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK).
Summary: Pheochromocytoma (PHEO) in multiple endocrine neoplasia type 1 (MEN1) is extremely rare. The incidence is reported as less than 2%. We report a case of a 76-year-old male with familial MEN1 who was found to have unilateral PHEO.
View Article and Find Full Text PDFProgressive Small Bowel Obstruction in a Patient With the Autoimmune Syndrome APECED.
Gastroenterology
July 2020
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland. Electronic address:
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
J Hepatol
March 2017
Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA. Electronic address:
Background & Aims: Tremelimumab is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. Ablative therapies induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced hepatocellular carcinoma (HCC). This study aimed to demonstrate whether tremelimumab could be combined safely and feasibly with ablation.
View Article and Find Full Text PDFHepatobiliary and Pancreatic: Not all that "Glisson's" is fat.
J Gastroenterol Hepatol
September 2016
Translational Hepatology Unit, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Liver Diseases Branch (LDB), Bethesda, Maryland, USA.
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.
Am J Hum Genet
May 2016
Department of Genetics and Computational Biology, QIMR Berghofer, Herston, QLD 4029, Australia. Electronic address:
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is an autosomal-dominant cancer-predisposition syndrome with a significant risk of gastric, but not colorectal, adenocarcinoma. We mapped the gene to 5q22 and found loss of the wild-type allele on 5q in fundic gland polyps from affected individuals. Whole-exome and -genome sequencing failed to find causal mutations but, through Sanger sequencing, we identified point mutations in APC promoter 1B that co-segregated with disease in all six families.
View Article and Find Full Text PDF